The Disrupters
Executive Summary
The endless cycle of mergers is no answer to the basic growth problems of now oversized pharmaceutical companies, in part because little real restructuring goes on with the acquirer, who needs it as much as the target. But one set of acquirers we haven't heard from could accomplish a lot of the necessary reforms: the large IT companies who could apply not only their technologies to improve marketing and business practices in the drug industry, but their management philosophies.